On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

Finally, blaming the pharmaceutical industry for high drug costs has historically been PBMs’ go-to defense. In a rebuttal to the FTC report issued in the summer, the PCMA criticized the ...

Pharmacy Benefit Managers (PBM) sit in the center of our prescription drug system, coordinating between insurance companies, ...

The Federal Trade Commission published a second interim staff report this week on the prescription drug middleman industry, which ...

Prescription drug prices are rising, and a new report from the Federal Trade Commission (FTC) explains why. Pharmacy benefit ...

In the report, the FTC said pharmacy benefit managers (PBMs), charge significant markups for cancer, HIV, and other critical ...

"Given the fact that there are states, counties, cities, school districts, pension funds, and other plaintiffs from all over ...